1: \begin{abstract}
2: Given the prominence of targeted therapy and immunotherapy in cancer treatment, it becomes imperative to consider heterogeneity in patients'
3: responses to treatments, which contributes greatly to the widely used proportional hazard assumption invalidated as observed in several
4: clinical trials. To address the challenge in the data analysis in oncology clinical trials, we develop a Dual Cox model theory including a
5: Dual Cox model and a fitting algorithm.
6:
7: As one of the finite mixture models, the proposed Dual Cox model consists of two independent Cox models based on patients' responses to one
8: designated treatment (usually the experimental one) in the clinical trial. Responses of patients in the designated treatment arm can be
9: observed and hence those patients are known responders or non-responders. From the perspective of subgroup classification, such a phenomenon
10: renders the proposed model as a semi-supervised problem, compared to the typical finite mixture model where the subgroup classification is
11: usually unsupervised.
12:
13: A specialized expectation-maximization algorithm is utilized for model fitting, where the initial parameter values are estimated from the
14: patients in the designated treatment arm and then the iteratively reweighted least squares (IRLS) is applied. Under mild assumptions, the
15: consistency and asymptotic normality of its estimators of effect parameters in each Cox model are established.
16:
17: In addition to strong theoretical properties, simulations demonstrate that our theory can provide a good approximation to a wide variety of
18: survival models, is relatively robust to the change of censoring rate and response rate, and has a high prediction accuracy and stability in
19: subgroup classification while it has a fast convergence rate. Finally, we apply our theory to two clinical trials with cross-overed KM plots
20: and identify the subgroups where the subjects benefit from the treatment or not.
21: \end{abstract}
22: